Clinical Trial Update: A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating nemolizumab for prurigo nodularis has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prurigo Nodularis

Drugs mentioned

• Nemolizumab (nemolizumab)

Snippet

Sponsor: Galderma R&D | Conditions: Prurigo Nodularis | Phase 3 | Status: COMPLETED | Results posted: 2024-07-10